InspireMD, Inc. (NSPR) |
| 0.4682 -0.032 (-6.36%) 10-14 16:00 |
| Open: | 0.484 |
| High: | 0.5 |
| Low: | 0.4604 |
| Volume: | 198,654 |
| Market Cap: | 22(M) |
| PE Ratio: | -0.73 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.82 |
| Resistance 1: | 0.68 |
| Pivot price: | 0.58 |
| Support 1: | 0.46 |
| Support 2: | 0.38 |
| 52w High: | 2.54 |
| 52w Low: | 0.46 |
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
| EPS | -0.620 |
| Book Value | 0.670 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.042 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -815.64 |
| Return on Assets (ttm) | -85.8 |
| Return on Equity (ttm) | -202.8 |
Sat, 10 Oct 2026
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 Level - Butterfly Setup - https://www.siam.in/
Sat, 10 Oct 2026
InspireMD (NSPR) Climbs 8.5% to $0.52 as Shares Reclaim the $0.50 Level - Momentum Trade - dars.gov.et
Thu, 01 Oct 2026
InspireMD (NASDAQ:NSPR) Will Have To Spend Its Cash Wisely - Simply Wall Street
Wed, 23 Sep 2026
Director Stuka Paul reports acquiring and disposing of two warrant series at InspireMD (NSPR). - Stock Titan
Mon, 21 Sep 2026
An anticipated FDA approval could open up $11 million for InspireMD's stroke-prevention device. - Stock Titan
Wed, 02 Sep 2026
InspireMD Inc. (NSPR) Peer Comparison – Compare with Others - Value Research
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |